Navigation Links
First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
Date:5/27/2008

Collaborative groups set out to confirm potential benefits of anticancer

therapies to treat women with breast cancer

PARIS, May 27 /PRNewswire/ -- A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin(R)) and the targeted therapy trastuzumab (Herceptin(R)), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

"Trastuzumab is already the standard of care across all stages of HER2-positive breast cancer and has a proven survival benefit. Bevacizumab has been shown to be of benefit when given in combination with chemotherapy for the treatment of metastatic breast cancer," said Dennis Slamon, MD, director of clinical/translational research at the University of California, Los Angeles' (UCLA) Jonsson Comprehensive Cancer Center and principal investigator, Cancer International Research Group. "The design of the BETH clinical trial is based on the preclinical and early clinical work from the Slamon/TRIO Laboratories at UCLA. We are looking forward to investigating the additional benefit to patients of combining these two treatments with chemotherapy in the treatment of early breast cancer."

"Despite treatment advances, over 400,000 women worldwide still die from breast cancer every year, so striving to improve treatment outcomes remains critical," said Norman Wolmark, MD, chairman of the Department of Human Oncology at the Allegheny General Hospital, and principal investigator, NSABP Foundation, Inc., Pittsburgh, Pennsylvania, USA, who welcomes the start of the study.

In BETH, patients will be randomized to a regimen of chemotherapy (either 6 cycles of docetaxel/carboplatin or 3 cycl
'/>"/>

SOURCE National Surgical Adjuvant Breast and Bowel Project
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... DIEGO, Aug. 12, 2011 / PRNewswire/ -- Halozyme ... company developing and commercializing products targeting the extracellular ... at the Wedbush 2011 Life Sciences Conference in New ... at 9:10 a.m. EDT (6:10 a.m. PDT). To listen ...
... WOODLANDS, Texas, Aug. 11, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... , Lexicon,s president and chief executive officer, will present ... on Tuesday, August 16, 2011 at 1:15 p.m. Eastern ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference 2
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... 2015 Recently, Weddingshe.com has added many trendy ... announced its highest annual revenues in the past three years. ... glamorous wedding dresses. , According to the sales manager of ... promotions for them in 2015. This point can be reflected ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Researchers at the University of Florida and Metagenics Inc. today ... combined with a low-glycemic, Mediterranean-style diet is almost twice as ... risk factors for cardiovascular disease, the leading cause of death ... medical food UltraMeal PLUS 360 is 40 percent more likely ...
... May 19 (HealthDay News) -- Summer fun can take a ... a common infection that accounts for almost $500 million in ... report. Swimmer,s ear results in 2.4 million doctor ... average of $200, according to the report from the U.S. ...
... FL (May 19, 2011)Researchers from the University of Miami (UM) ... different teaching models for children with Autism Spectrum Disorder (ASD). ... the fidelity of treatment models for preschoolers with autism. ... the journal Research in Autism Spectrum Disorders . ...
... ARBOR, Mich. A primary reason that head and neck ... chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive ... Indian spice curcumin can help cells overcome that resistance. ... head and neck cancer cell lines, they were able to ...
... have been diagnosed with poor sperm quality and who are ... Researchers have found that while cell phone use appears to ... may also lead to low sperm quality and a decrease ... puzzling," says Rany Shamloul, a postdoctoral fellow in the Department ...
... Crohn,s patients in a research study at Penn ... a chronic inflammatory condition of the gastrointestinal tract ... loss. Treatments for Crohn,s disease are designed to ... rare but serious side effects, including infections and ...
Cached Medicine News:Health News:Breakthrough medical food reverses risk of heart disease and diabetes 2Health News:Breakthrough medical food reverses risk of heart disease and diabetes 3Health News:Swimmer's Ear Costs Up to $500 Million a Year in U.S. 2Health News:Validating preschool programs for children with autism 2Health News:Curcumin compound improves effectiveness of head and neck cancer treatment, U-M study finds 2Health News:Use of naltrexone reduces inflammation in Crohn's patients 2
... used as an adjunct to suture anchors ... bone to speed healing and strengthen the ... over a greater area dramatically improves soft ... disc of bioabsorbable PLLA has an extremely ...
... new generation of polyester suture with a ... strength than similar sized polyester suture with ... knot profile. FiberWire is the ideal suture ... eliminating suture breakage during knot tying.,All sizes ...
... an easy one step approach to creating ... the Bio-Tenodesis Driver. Instead of using a ... retrograde through the tip of the Bio-Tenodesis ... as a suture shuttle for passage of ...
... is a new portable digital flowmeter designed for ... simplicity and cost effectiveness are top priorities.Flowmaster is ... easy to give a patient some privacy. Simply ... will be send wirelessly to the computer. No ...
Medicine Products: